Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CET

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
11:58p NETSUITE : Three Vital Questions for Finding the Right Resource Management Process
11:58p INFIGEN ENERGY : Secures PPA for 113 MW Bodangora Wind Farm Project
11:58p NORWAY : A Case Study for EV Incentives
11:58p OURPET : 02.27.17 OurPet’s Company Reports Record Fourth Quarter 2016 Results
11:58p TEXTRON : Aviation features leading products, mission capabilities at Avalon 2017
11:56p MOBIUS INSTITUTE : Announces the 2017 International Machine Vibration Analysis Conference (IMVAC) AUSTRALIA Will Be Held in Gold Coast
11:56p YHOO ALERT : Rosen Law Firm Reminds Yahoo! Inc. Investors of Important Deadline in Class Action - YHOO
11:55p INTEGER : beats Street 4Q forecasts
11:55p Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against DaVita Inc. – DVA
11:54p HERITAGE-CRYSTAL CLEAN, INC. (NASDAQ : HCCI) Files An 8-K Entry into a Material Definitive Agreement
Latest news
Advertisement
Hot News 
2.31%ESURE : UK insurer esure Group sees 2016 profit ahead of expectations
-7.16%DIRECT LINE INSURANCE : expects lower profit before tax due to discount rate change
-9.64%TRINITY MIRROR : to accelerate digital strategy after print decline
3.41%BUNZL : British distributor Bunzl eyes Trump boost in 2017
-2.46%FTSE ends higher on some positive earnings, insurers slip
Most Read News
04:36p Dow hits 12th record high close; Trump talks up infrastructure spending
11:50a LSE scuppers Deutsche Boerse merger hopes by rejecting EU demand
12:32p Buffett's Berkshire more than doubled its stake in Apple - CNBC
04:38a BANK VTB : Russia's VTB plans to slim down in Europe, keep London as hub
08:20a ING GROEP : Euro zone banks cut cross-border lending as stability fears grow
Most recommended articles
04:58a Amazon, Netflix grab a share of Oscar glory
02/23DJVIVENDI : Full-Year Earnings Beat Estimates
05:53pDJGRAIN HIGHLIGHTS : Top Stories of the Day
05:52p JPMorgan, Microsoft, Intel and others form new blockchain alliance
05:42pDJUSDA Ark/Louisiana/Tex/Calif Weekly Rice Review - Feb 27